Emerging role of IκBζ in inflammation: Emphasis on psoriasis

Abstract Psoriasis is a chronic inflammatory disorder affecting skin and joints that results from immunological dysfunction such as enhanced IL‐23 induced Th‐17 differentiation. IkappaB‐Zeta (IκBζ) is an atypical transcriptional factor of the IκB protein family since, contrary to the other family me...

Full description

Bibliographic Details
Main Authors: Preeti Gautam, Sylvain Maenner, Frédéric Cailotto, Pascal Reboul, Stéphane Labialle, Jean‐Yves Jouzeau, Frédéric Bourgaud, David Moulin
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Clinical and Translational Medicine
Subjects:
Online Access:https://doi.org/10.1002/ctm2.1032
_version_ 1797988904702312448
author Preeti Gautam
Sylvain Maenner
Frédéric Cailotto
Pascal Reboul
Stéphane Labialle
Jean‐Yves Jouzeau
Frédéric Bourgaud
David Moulin
author_facet Preeti Gautam
Sylvain Maenner
Frédéric Cailotto
Pascal Reboul
Stéphane Labialle
Jean‐Yves Jouzeau
Frédéric Bourgaud
David Moulin
author_sort Preeti Gautam
collection DOAJ
description Abstract Psoriasis is a chronic inflammatory disorder affecting skin and joints that results from immunological dysfunction such as enhanced IL‐23 induced Th‐17 differentiation. IkappaB‐Zeta (IκBζ) is an atypical transcriptional factor of the IκB protein family since, contrary to the other family members, it positively regulates NF‐κB pathway by being exclusively localized into the nucleus. IκBζ deficiency reduces visible manifestations of experimental psoriasis by diminishing expression of psoriasis‐associated genes. It is thus tempting to consider IκBζ as a potential therapeutic target for psoriasis as well as for other IL23/IL17‐mediated inflammatory diseases. In this review, we will discuss the regulation of expression of NFKBIZ and its protein IκBζ, its downstream targets, its involvement in pathogenesis of multiple disorders with emphasis on psoriasis and evidences supporting that inhibition of IκBζ may be a promising alternative to current therapeutic managements of psoriasis.
first_indexed 2024-04-11T08:11:34Z
format Article
id doaj.art-6e3061e5bae947cc9214460e37c13b23
institution Directory Open Access Journal
issn 2001-1326
language English
last_indexed 2024-04-11T08:11:34Z
publishDate 2022-10-01
publisher Wiley
record_format Article
series Clinical and Translational Medicine
spelling doaj.art-6e3061e5bae947cc9214460e37c13b232022-12-22T04:35:21ZengWileyClinical and Translational Medicine2001-13262022-10-011210n/an/a10.1002/ctm2.1032Emerging role of IκBζ in inflammation: Emphasis on psoriasisPreeti Gautam0Sylvain Maenner1Frédéric Cailotto2Pascal Reboul3Stéphane Labialle4Jean‐Yves Jouzeau5Frédéric Bourgaud6David Moulin7Laboratoire IMoPA UMR 7365 CNRS‐Université de Lorraine, Biopôle de l'Université de Lorraine Vandœuvre‐lès‐Nancy FranceLaboratoire IMoPA UMR 7365 CNRS‐Université de Lorraine, Biopôle de l'Université de Lorraine Vandœuvre‐lès‐Nancy FranceLaboratoire IMoPA UMR 7365 CNRS‐Université de Lorraine, Biopôle de l'Université de Lorraine Vandœuvre‐lès‐Nancy FranceLaboratoire IMoPA UMR 7365 CNRS‐Université de Lorraine, Biopôle de l'Université de Lorraine Vandœuvre‐lès‐Nancy FranceLaboratoire IMoPA UMR 7365 CNRS‐Université de Lorraine, Biopôle de l'Université de Lorraine Vandœuvre‐lès‐Nancy FranceLaboratoire IMoPA UMR 7365 CNRS‐Université de Lorraine, Biopôle de l'Université de Lorraine Vandœuvre‐lès‐Nancy FranceTemisis Therapeutics Vandœuvre‐lès‐Nancy FranceLaboratoire IMoPA UMR 7365 CNRS‐Université de Lorraine, Biopôle de l'Université de Lorraine Vandœuvre‐lès‐Nancy FranceAbstract Psoriasis is a chronic inflammatory disorder affecting skin and joints that results from immunological dysfunction such as enhanced IL‐23 induced Th‐17 differentiation. IkappaB‐Zeta (IκBζ) is an atypical transcriptional factor of the IκB protein family since, contrary to the other family members, it positively regulates NF‐κB pathway by being exclusively localized into the nucleus. IκBζ deficiency reduces visible manifestations of experimental psoriasis by diminishing expression of psoriasis‐associated genes. It is thus tempting to consider IκBζ as a potential therapeutic target for psoriasis as well as for other IL23/IL17‐mediated inflammatory diseases. In this review, we will discuss the regulation of expression of NFKBIZ and its protein IκBζ, its downstream targets, its involvement in pathogenesis of multiple disorders with emphasis on psoriasis and evidences supporting that inhibition of IκBζ may be a promising alternative to current therapeutic managements of psoriasis.https://doi.org/10.1002/ctm2.1032psoriasisikappabZeta, IκBζinflammationNFKBIZ
spellingShingle Preeti Gautam
Sylvain Maenner
Frédéric Cailotto
Pascal Reboul
Stéphane Labialle
Jean‐Yves Jouzeau
Frédéric Bourgaud
David Moulin
Emerging role of IκBζ in inflammation: Emphasis on psoriasis
Clinical and Translational Medicine
psoriasis
ikappabZeta, IκBζ
inflammation
NFKBIZ
title Emerging role of IκBζ in inflammation: Emphasis on psoriasis
title_full Emerging role of IκBζ in inflammation: Emphasis on psoriasis
title_fullStr Emerging role of IκBζ in inflammation: Emphasis on psoriasis
title_full_unstemmed Emerging role of IκBζ in inflammation: Emphasis on psoriasis
title_short Emerging role of IκBζ in inflammation: Emphasis on psoriasis
title_sort emerging role of iκbζ in inflammation emphasis on psoriasis
topic psoriasis
ikappabZeta, IκBζ
inflammation
NFKBIZ
url https://doi.org/10.1002/ctm2.1032
work_keys_str_mv AT preetigautam emergingroleofikbzininflammationemphasisonpsoriasis
AT sylvainmaenner emergingroleofikbzininflammationemphasisonpsoriasis
AT fredericcailotto emergingroleofikbzininflammationemphasisonpsoriasis
AT pascalreboul emergingroleofikbzininflammationemphasisonpsoriasis
AT stephanelabialle emergingroleofikbzininflammationemphasisonpsoriasis
AT jeanyvesjouzeau emergingroleofikbzininflammationemphasisonpsoriasis
AT fredericbourgaud emergingroleofikbzininflammationemphasisonpsoriasis
AT davidmoulin emergingroleofikbzininflammationemphasisonpsoriasis